

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit : 1635
Examiner : Louis V. Wollenberger
Applicant : Nariyoshi Shinomiya et al.
Appln. No. : 10/599,327
Filing Date : March 12, 2007
Confirmation No. : 7013
For : *c-met* siRNA ADENOVIRUS VECTORS INHIBIT CANCER CELL
GROWTH, INVASION AND TUMORIGENICITY

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

RESPONSE AND AMENDMENT

In response to the Office Action mailed January 14, 2009 ("Office Action"), please consider the following response. The Office Action states (a) restriction is required under 35 U.S.C. §121 and 372 and (b) applicant is required, in reply to this action, to elect a single method thereof---i.e., a single tumor or cancer from claims 48 and 50---to which the claims must be restricted" (Office Action, pp. 3-4). Accordingly, as to claims 48 and 50, Applicants elect a glioblastoma tumor or cancer.

Additionally, the Office Action indicates the sequence listing fails to comply with 37 CFR 1.821-1.825. As such, Applicants herewith submit a substitute computer readable form (CRF) of the sequence listing under the file name "Amended Sequence Listing.TXT", created February 12, 2009, and which has a file size of 38,332 bytes. The content of the substitute Sequence Listing includes no new matter. Applicant requests entry of the substitute Sequence Listing submitted herewith into the application.

Applicant : Nariyoshi Shinomiya et al.
For : *c-met* siRNA ADENOVIRUS VECTORS INHIBIT CANCER CELL
GROWTH, INVASION AND TUMORIGENICITY
Page : 2

All pending claims are believed to be in condition for allowance, and a Notice of Allowability is therefore earnestly solicited.

Respectfully submitted,

February 13, 2009

Date

/Douglas H. Siegel/

Douglas H. Siegel, Registration No. 34 251
Price, Heneveld, Cooper, DeWitt & Litton, LLP
695 Kenmoor, S.E.
Post Office Box 2567
Grand Rapids, Michigan 49501
(616) 949-9610

DHS/alw